Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

The Wolverine Stack just got a green light from the FDA. An advisory panel voted to recommend both BPC-157 and TB-500 for the compounding bulk substances list. And honestly, it's not surprising once you understand this stack: (1/11)

realpeptides's profile picture

Real Peptides®️

16,972 subscribers

85,339 Aufrufe • vor 1 Monat •via X (Twitter)

Wissenschaft & TechnologieGesundheit & Wellness
LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

BPC-157 and TB-500 are two of the most talked-about peptides in fitness, bodybuilding, and biohacking. Together they’re often called the “Wolverine Stack” — a peptide combination rumored to dramatically accelerate healing of tendons, ligaments, muscles, and injuries. But do BPC-157 and TB-500 actually work in humans, or is the Wolverine Stack just another example of internet bro-science? In this evidence-based deep dive, Dr. Alex Tatem (board-certified urologist and men’s health specialist) breaks down the real science behind BPC-157 and TB-500 — including their biochemical mechanisms, animal research, potential healing effects, safety concerns, and why pharmaceutical companies have never brought these peptides through full FDA clinical trials. We explore the nitric oxide signaling, angiogenesis, VEGF pathways, actin regulation, and tissue repair biology behind these compounds and explain why rodent studies look promising — but why human clinical evidence is still extremely limited. You’ll also learn about: • What BPC-157 (Body Protection Compound-157) actually is • TB-500 vs Thymosin Beta-4 explained • The origin of the Wolverine Stack peptide protocol • Peptides for tendon healing and ligament injuries • BPC-157 for gut healing and musculoskeletal repair • TB-500 and actin-mediated tissue regeneration • Why most peptide research comes from one Croatian research group • The patent law problem preventing pharmaceutical development • Real risks of grey-market peptide contamination • Why WADA bans BPC-157 and TB-500 in competitive athletes • Theoretical cancer risks related to angiogenesis • What the current scientific literature actually shows If you've ever searched: “Does BPC-157 work?” “What is TB-500?” “Peptides for healing injuries” “BPC-157 tendon repair” “Wolverine Stack peptides explained” — this video breaks down the science. The peptides may be promising. But promise and proof are not the same thing. Drop a comment below: Have you ever used BPC-157, TB-500, or other peptides? What was your experience? 👍 Like the video if you want more evidence-based breakdowns of supplements, PEDs, and peptides. Subscribe for deep dives on testosterone, steroids, peptides, supplements, and men’s health science.
30:26

BPC-157 and TB-500 are two of the most talked-about peptides in fitness, bodybuilding, and biohacking. Together they’re often called the “Wolverine Stack” — a peptide combination rumored to dramatically accelerate healing of tendons, ligaments, muscles, and injuries. But do BPC-157 and TB-500 actually work in humans, or is the Wolverine Stack just another example of internet bro-science? In this evidence-based deep dive, Dr. Alex Tatem (board-certified urologist and men’s health specialist) breaks down the real science behind BPC-157 and TB-500 — including their biochemical mechanisms, animal research, potential healing effects, safety concerns, and why pharmaceutical companies have never brought these peptides through full FDA clinical trials. We explore the nitric oxide signaling, angiogenesis, VEGF pathways, actin regulation, and tissue repair biology behind these compounds and explain why rodent studies look promising — but why human clinical evidence is still extremely limited. You’ll also learn about: • What BPC-157 (Body Protection Compound-157) actually is • TB-500 vs Thymosin Beta-4 explained • The origin of the Wolverine Stack peptide protocol • Peptides for tendon healing and ligament injuries • BPC-157 for gut healing and musculoskeletal repair • TB-500 and actin-mediated tissue regeneration • Why most peptide research comes from one Croatian research group • The patent law problem preventing pharmaceutical development • Real risks of grey-market peptide contamination • Why WADA bans BPC-157 and TB-500 in competitive athletes • Theoretical cancer risks related to angiogenesis • What the current scientific literature actually shows If you've ever searched: “Does BPC-157 work?” “What is TB-500?” “Peptides for healing injuries” “BPC-157 tendon repair” “Wolverine Stack peptides explained” — this video breaks down the science. The peptides may be promising. But promise and proof are not the same thing. Drop a comment below: Have you ever used BPC-157, TB-500, or other peptides? What was your experience? 👍 Like the video if you want more evidence-based breakdowns of supplements, PEDs, and peptides. Subscribe for deep dives on testosterone, steroids, peptides, supplements, and men’s health science.

Dr. Alex Tatem

22,510 Aufrufe • vor 6 Monaten

Today I testified before the FDA's Pharmacy Compounding Advisory Committee to advocate for patient access to BPC-157, TB-500, KPV, and MOTS-c. The committee voted to recommend moving all four peptides forward—but this is not final FDA approval. There are still important steps ahead. I break down exactly what happened, what this vote actually means, and what comes next.👇
5:40

Today I testified before the FDA's Pharmacy Compounding Advisory Committee to advocate for patient access to BPC-157, TB-500, KPV, and MOTS-c. The committee voted to recommend moving all four peptides forward—but this is not final FDA approval. There are still important steps ahead. I break down exactly what happened, what this vote actually means, and what comes next.👇

Dr. Alex Tatem

44,501 Aufrufe • vor 1 Monat

Oral BPC-157 Let’s learn about it! Here’s a short clip from Stack Peptide Certification Course that I am debuting in mid-July, just before several major peptides, including BPC-157, are set to be available again from compounding pharmacies here in the US. In the course I will be doing this type of breakdown and discussion for every major peptide (40-50+). If you are interested in joining the waiting list for the course, see the link below.
3:09

Oral BPC-157 Let’s learn about it! Here’s a short clip from Stack Peptide Certification Course that I am debuting in mid-July, just before several major peptides, including BPC-157, are set to be available again from compounding pharmacies here in the US. In the course I will be doing this type of breakdown and discussion for every major peptide (40-50+). If you are interested in joining the waiting list for the course, see the link below.

Jesse Morse, M.D.

45,539 Aufrufe • vor 3 Monaten

Real talk — I’ve been thinking about the Wolverine stack and it makes zero sense to me to put BPC-157 and TB-500 in the same vial. These two have totally different half-lives and ideal dosing schedules. BPC wants to be in there daily, TB-500 shines with bigger doses a couple times a week. Locking them together in one vial forces you into one fixed ratio and one schedule for both — you can’t tweak or taper them independently. Why give up that control? Somebody convince me I’m wrong. What’s the actual advantage of pre-mixing them
1:14

Real talk — I’ve been thinking about the Wolverine stack and it makes zero sense to me to put BPC-157 and TB-500 in the same vial. These two have totally different half-lives and ideal dosing schedules. BPC wants to be in there daily, TB-500 shines with bigger doses a couple times a week. Locking them together in one vial forces you into one fixed ratio and one schedule for both — you can’t tweak or taper them independently. Why give up that control? Somebody convince me I’m wrong. What’s the actual advantage of pre-mixing them

Chris G.

18,507 Aufrufe • vor 1 Monat

BPC-157 causing cancer? FDA shutting down peptide trials? “No human RCTs have ever been done on peptides?” In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on Shawn Ryan Show about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety. We break down: • Whether BPC-157 actually causes cancer • The truth about angiogenesis and tumor growth • FDA regulation of peptides and compounding • Why the “no randomized controlled trials” claim is completely false • Human clinical trial data on peptides • The real history of BPC-157 clinical studies • Huberman’s correction of viral peptide misinformation • Why peptide fearmongering could push patients toward unsafe gray-market sourcing This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine. Topics covered include: BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, Andrew D. Huberman, Ph.D. , Shawn Ryan Show, FDA peptide regulation, growth hormone history, and performance medicine. If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.
20:43

BPC-157 causing cancer? FDA shutting down peptide trials? “No human RCTs have ever been done on peptides?” In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on Shawn Ryan Show about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety. We break down: • Whether BPC-157 actually causes cancer • The truth about angiogenesis and tumor growth • FDA regulation of peptides and compounding • Why the “no randomized controlled trials” claim is completely false • Human clinical trial data on peptides • The real history of BPC-157 clinical studies • Huberman’s correction of viral peptide misinformation • Why peptide fearmongering could push patients toward unsafe gray-market sourcing This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine. Topics covered include: BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, Andrew D. Huberman, Ph.D. , Shawn Ryan Show, FDA peptide regulation, growth hormone history, and performance medicine. If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.

Dr. Alex Tatem

77,332 Aufrufe • vor 3 Monaten

Hims & Hers Health shares fell over 11% after an FDA advisory panel voted 7 to 6 against adding Emideltide to the compounding 503A Bulks List. THE IMPACT: The narrow rejection raises near-term regulatory hurdles for compounding pharmacy operators looking to offer customized peptide therapies. FUNDAMENTALS: Core operations remain strong, supported by $2.37B in total revenue and a high 72.92% gross margin. THE RATING: Regulatory uncertainty keeps the Seeking Alpha Quant score at a neutral HOLD. Will $HIMS overcome these regulatory hurdles with its expanded pharmacy compounding strategy?
0:29

Hims & Hers Health shares fell over 11% after an FDA advisory panel voted 7 to 6 against adding Emideltide to the compounding 503A Bulks List. THE IMPACT: The narrow rejection raises near-term regulatory hurdles for compounding pharmacy operators looking to offer customized peptide therapies. FUNDAMENTALS: Core operations remain strong, supported by $2.37B in total revenue and a high 72.92% gross margin. THE RATING: Regulatory uncertainty keeps the Seeking Alpha Quant score at a neutral HOLD. Will $HIMS overcome these regulatory hurdles with its expanded pharmacy compounding strategy?

Seeking Alpha

10,339 Aufrufe • vor 1 Monat

BPC-157 is the peptide almost everyone starts with. Here is my full masterclass on it. 00:00 Intro and why BPC-157 01:44 What BPC-157 actually is 03:58 How it works in the body 07:32 Healing, inflammation and the brain 12:18 Who it is for and who skips it 14:20 Contraindications and cautions 15:52 Dosing tiers and timing 19:50 Cycling and time off 23:16 Pairing and the Wolverine stack 25:14 Reconstitution and injection 30:44 Troubleshooting and side effects 33:34 Legal status and FDA update 34:44 Oral vs injectable 36:20 The cancer debate 44:34 Final verdict
47:17

BPC-157 is the peptide almost everyone starts with. Here is my full masterclass on it. 00:00 Intro and why BPC-157 01:44 What BPC-157 actually is 03:58 How it works in the body 07:32 Healing, inflammation and the brain 12:18 Who it is for and who skips it 14:20 Contraindications and cautions 15:52 Dosing tiers and timing 19:50 Cycling and time off 23:16 Pairing and the Wolverine stack 25:14 Reconstitution and injection 30:44 Troubleshooting and side effects 33:34 Legal status and FDA update 34:44 Oral vs injectable 36:20 The cancer debate 44:34 Final verdict

Hunter Williams

27,198 Aufrufe • vor 2 Monaten

The FDA’s recent recommendations on peptides are a *significant* setback for new and existing companies being built around the expectation that they will be able to sell compounded peptides. That’s because the 503A Bulks List is basically a pathway that lets compounding pharmacies use certain bulk drug substances to compound drugs for patient-specific prescriptions. The FDA is recommending against adding seven popular peptides to the list. Unless RFK goes against the FDA staff recommendation, these companies’ path to legally compounding and selling peptides becomes very difficult.
2:58

The FDA’s recent recommendations on peptides are a *significant* setback for new and existing companies being built around the expectation that they will be able to sell compounded peptides. That’s because the 503A Bulks List is basically a pathway that lets compounding pharmacies use certain bulk drug substances to compound drugs for patient-specific prescriptions. The FDA is recommending against adding seven popular peptides to the list. Unless RFK goes against the FDA staff recommendation, these companies’ path to legally compounding and selling peptides becomes very difficult.

TBPN

48,450 Aufrufe • vor 2 Monaten

I would take KPV over BPC-157 and TB-500 any day. Here's my full masterclass on it. 03:24 What KPV actually is and where it comes from 05:34 NF-kappa B: the master inflammation switch KPV shuts off 07:54 Why KPV targets inflamed tissue and leaves healthy tissue alone 11:48 Who benefits: IBD, Crohn's, ulcerative colitis 12:56 Breaking the BPC and TB-500 plateau 14:02 Autoimmune, skin conditions and MCAS 15:42 Dosing Tier 1: 250mcg 16:54 Dosing Tier 2: 500mcg for active healing 17:16 Dosing Tier 3: 1mg+ for severe inflammation 26:56 Sequencing: calm the fire before you rebuild 31:36 Stacking with BPC-157, TB-500, LL-37 and GLPs 40:34 Long COVID and MCAS 43:20 KPV is the peptide that calms the room
46:46

I would take KPV over BPC-157 and TB-500 any day. Here's my full masterclass on it. 03:24 What KPV actually is and where it comes from 05:34 NF-kappa B: the master inflammation switch KPV shuts off 07:54 Why KPV targets inflamed tissue and leaves healthy tissue alone 11:48 Who benefits: IBD, Crohn's, ulcerative colitis 12:56 Breaking the BPC and TB-500 plateau 14:02 Autoimmune, skin conditions and MCAS 15:42 Dosing Tier 1: 250mcg 16:54 Dosing Tier 2: 500mcg for active healing 17:16 Dosing Tier 3: 1mg+ for severe inflammation 26:56 Sequencing: calm the fire before you rebuild 31:36 Stacking with BPC-157, TB-500, LL-37 and GLPs 40:34 Long COVID and MCAS 43:20 KPV is the peptide that calms the room

Hunter Williams

30,680 Aufrufe • vor 2 Monaten

FREEMASONRY: FROM DARKNESS TO LIGHT To understand the present you must first understand the past. 2 Corinthians 11:14 “And no marvel; for Satan himself is transformed into an angel of light.”
38:42

FREEMASONRY: FROM DARKNESS TO LIGHT To understand the present you must first understand the past. 2 Corinthians 11:14 “And no marvel; for Satan himself is transformed into an angel of light.”

Redpill Drifter

20,431 Aufrufe • vor 1 Jahr

$HIMS 🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY Peptides insider Jesse Morse, M.D. expects approval We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS 01:37 - FDA briefing document 03:24 - Getting peptides back in front of the FDA 08:58 - Prescribing peptides back in 2017 12:42 - Peptides safety data 16:08 - BPC-157 deep-dive and odds for approval 22:56 - TB-500 deep-dive 26:15 - Approval odds for the other 5 peptides 31:02 - Peptide efficacy data 34:40 - FDA politics and final decisions 40:30 - Peptides market size 42:48 - Training the doctors 47:20 - Shipping hurdles and gray-market risk 53:25 - Why peptides could reshape healthcare Not financial, legal, or medical advice
1:01:13

$HIMS 🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY Peptides insider Jesse Morse, M.D. expects approval We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS 01:37 - FDA briefing document 03:24 - Getting peptides back in front of the FDA 08:58 - Prescribing peptides back in 2017 12:42 - Peptides safety data 16:08 - BPC-157 deep-dive and odds for approval 22:56 - TB-500 deep-dive 26:15 - Approval odds for the other 5 peptides 31:02 - Peptide efficacy data 34:40 - FDA politics and final decisions 40:30 - Peptides market size 42:48 - Training the doctors 47:20 - Shipping hurdles and gray-market risk 53:25 - Why peptides could reshape healthcare Not financial, legal, or medical advice

Hims House

185,254 Aufrufe • vor 1 Monat

This peptide stack literally revived my 14-year-old dog: BPC-157 + TB-500 We gave him 1-2 mg a day, 5 days on, 2 days off, injecting him basically the same way you'd inject a human. Later, we added TRT. 6 months ago, he was limping, achy, getting up slowly, and couldn't jump on the couch. Today, our boy is running, jumping on the patio, going on long walks again, and even his hearing is back. And he is the most measured dog on the planet!
0:26

This peptide stack literally revived my 14-year-old dog: BPC-157 + TB-500 We gave him 1-2 mg a day, 5 days on, 2 days off, injecting him basically the same way you'd inject a human. Later, we added TRT. 6 months ago, he was limping, achy, getting up slowly, and couldn't jump on the couch. Today, our boy is running, jumping on the patio, going on long walks again, and even his hearing is back. And he is the most measured dog on the planet!

Michael Morelli

77,818 Aufrufe • vor 11 Tagen

Retatrutide is the ultimate gateway peptide. Once you try it, everything changes. Appetite obliterated, fat melting off, energy steady, and it opens the door to the full biohacking stack. I’m down 31 lbs in 11 weeks. This isn’t just another GLP-1 — it’s next level.
1:06

Retatrutide is the ultimate gateway peptide. Once you try it, everything changes. Appetite obliterated, fat melting off, energy steady, and it opens the door to the full biohacking stack. I’m down 31 lbs in 11 weeks. This isn’t just another GLP-1 — it’s next level.

Biotides

23,346 Aufrufe • vor 2 Monaten

DeFi infrastructure has matured, but a B+ rated Balancer pool still got exploited. The panel explored defense-in-depth mechanisms, bridged asset risks, the insurance adoption gap, and who's actually responsible for securing the stack. From Infra Gardens Buenos Aires.
45:12

DeFi infrastructure has matured, but a B+ rated Balancer pool still got exploited. The panel explored defense-in-depth mechanisms, bridged asset risks, the insurance adoption gap, and who's actually responsible for securing the stack. From Infra Gardens Buenos Aires.

DIA | Cross-Chain Oracles for Web3

10,644 Aufrufe • vor 9 Monaten

If Lane Kiffin is making a pros and cons list for his next move LSU... the LSU pros stack up pretty quickly. (This is not me lobbying for him to leave Ole Miss)
1:34

If Lane Kiffin is making a pros and cons list for his next move LSU... the LSU pros stack up pretty quickly. (This is not me lobbying for him to leave Ole Miss)

J.D. PicKell

202,489 Aufrufe • vor 9 Monaten

💸 Microsoft for Startups Founders just handed Cryptify AI a $25,000 grant. They reviewed how we’re building on their stack and gave us the green light. Now we're backed by Azure's best — $25K in credits, expert support, and the tools to supercharge $CRAI to the next level. 🧠💥
0:26

💸 Microsoft for Startups Founders just handed Cryptify AI a $25,000 grant. They reviewed how we’re building on their stack and gave us the green light. Now we're backed by Azure's best — $25K in credits, expert support, and the tools to supercharge $CRAI to the next level. 🧠💥

Cryptify AI

148,256 Aufrufe • vor 1 Jahr

Look what we got here... it's a box from the Tulane Green Wave! I never understood the combination of light blue and green, but for some reason it works! Thank you Coach Sumrall and Tulane Football for all this awesome stuff, I'll be showing it off to all my friends!
3:48

Look what we got here... it's a box from the Tulane Green Wave! I never understood the combination of light blue and green, but for some reason it works! Thank you Coach Sumrall and Tulane Football for all this awesome stuff, I'll be showing it off to all my friends!

Jon Gruden

264,945 Aufrufe • vor 1 Jahr

Dr. Rhonda Patrick (Dr. Rhonda Patrick) shares her MUST-HAVE list of supplements for general health and longevity. If you were stranded on an island, this is the stack you'd want to take with you 👇
9:50

Dr. Rhonda Patrick (Dr. Rhonda Patrick) shares her MUST-HAVE list of supplements for general health and longevity. If you were stranded on an island, this is the stack you'd want to take with you 👇

Dan Bongino

230,670 Aufrufe • vor 4 Monaten